1

1 Brief Communication

5

- 2 Early Life Safety Profiling of Gene Therapy for Spinal Muscular Atrophy: A Case Series Analysis
- 3 Rebecca G. Spellman<sup>1,2</sup>, Leillani L. Ha<sup>1,2</sup>, Salomé Da Silva Duarte Lepez<sup>1,2</sup>, Elizabeth A. Arruda<sup>1,2</sup>, Emma
- 4 Rodrigues<sup>1,2</sup>, Kathryn J. Swoboda<sup>1,2,3,\*</sup>, Christiano R. R. Alves<sup>1,2,3,\*</sup>
- 6 <sup>1</sup> Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- <sup>2</sup> Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
- 8 <sup>3</sup> Department of Neurology, Harvard Medical School, Boston, MA, USA
- 9 \*Equal contribution and co-corresponding authors: <u>katswobo@gmail.com</u> and <u>calves2@mgh.harvard.edu</u>

### **Abstract**

The present study examines the safety profile of intravenous onasemnogene abeparvovec gene therapy in a real world setting, both alone or in combination with intrathecal antisense oligonucleotide nusinersen therapy in two cohorts of patients with spinal muscular atrophy (SMA). The first cohort included 8 presymptomatic infants treated solely with onasemnogene abeparvovec, while the second cohort comprised 6 symptomatic infants receiving onasemnogene abeparvovec and nusinersen co-therapy. All patients received the corticosteroid prednisolone coincident with gene therapy. Circulating alanine aminotransferase (ALT) and aspartate transaminase (AST) levels were measured to determine potential hepatoxicity, the primary focus of this study. Elevated ALT and AST levels, but no change in GGT levels were observed in 1 pre-symptomatic and 3 symptomatic patients post-treatment. However, all values normalized within three months of onasemnogene abeparvovec injection. Nusinersen treatment received previously or coincident with gene therapy did not impact the elevation of liver transaminases, which was transient. This study highlights the importance of early intervention with molecular treatments for SMA and indicates that prior or coincident treatment with nusinersen is unlikely to impact safety of onasemnogene apoparvovec and could theoretically improve clinical outcomes in symptomatic infants or in those with gene therapy delayed beyond the immediate neonatal period.

**Keywords:** Neuromuscular diseases; SMA; Neurogenetics; Hepatotoxicity.

3

## Introduction

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

Molecular therapies have demonstrated remarkable clinical benefits when administered during the presymptomatic or early symptomatic stages of spinal muscular atrophy (SMA), significantly improving survival rates even among the most severely affected infants1. In 2016, nusinersen (Spinraza, Biogen) became the first molecular therapy approved for SMA, and numerous studies have since confirmed its efficacy and safety across various SMA populations<sup>2,3</sup>. In 2019, the U.S. Food and Drug Administration (FDA) approved onasemnogene abeparvovec (Zolgensma, Novartis/AVXS-101, AveXis), a gene therapy using an adenoassociated virus vector to deliver the SMN1 gene through a single intravenous injection in newborns and infants with SMA. Recent clinical trials have validated the effectiveness of onasemnogene abeparvovec in both pre-symptomatic and symptomatic infants, showing significant motor function improvements<sup>4-6</sup>. Over the past three years, this has largely become the treatment of choice for monotherapy in newborns with homozygous SMN1 deletion, regardless of SMN2 copy number. While gene therapy is a transformative treatment for SMA, varying adverse effects are observed: most commonly categorized as mild or moderate in severity these adverse events need to be closely monitored<sup>4-6</sup>. Despite limited data on the safety or long term outcomes of sequential overlapping or combinatorial treatment, there is an increasing number of infants receiving dual or sequential therapy with gene therapy and either nusinersen or risdiplam, an issue not adequately addressed yet in published clinical trials or studies. One of the potentially largest adverse impact on long term efficacy of gene therapy treatment in newborns with 2 SMN2 copies are the delays inherent in obtaining preauthorization, approval, and required preliminary safety testing prior to administration of AAV-9 mediated gene therapy. For a proportion of newborns, their catabolic state, variable transition to appropriate weight gain and social factors in the critical post-partum period, immediate dosing post birth may be neither ideal nor feasible. Thus adequate processes for rapid initiation of an alternative molecular therapy need to be standardized, and would ideally include overlapping coverage through the duration of the viral transduction process post dosing with AAV9-mediated intravenously delivered gene therapy. The most common adverse effect reported with onasemnogene abeparvovec gene therapy is elevated liver enzyme levels, which can indicate acute liver injury<sup>7,8</sup>. In clinical practice, these elevated levels are usually managed effectively with co-administration of prednisolone, a corticosteroid hormone<sup>8,9</sup>. Clinical trials have

4

demonstrated that initiating prednisolone 48 hours prior to gene therapy dosing and adjusting as needed for 2-3 months while closely monitoring liver function can successfully avoid serious medical consequences<sup>10</sup>. However, further longitudinal research is needed to fully understand the implications and risk of serious consequences at the extremes of age and weight not included in clinical trials.

Combinatorial therapies for SMA patients could be used more strategically to facilitate maximum rescue of at-risk motor neurons and other tissues<sup>11</sup>. The current approach in the clinical setting in the U.S. has been to choose one therapy, and then only consider adding another therapy if the first therapy proves to have insufficient benefit. In newborns identified by newborn screening, timing of gene therapy initiation is variable, but not infrequently delayed several weeks. In an infant with 2 SMN2 copies, this could lead to substantial progression of motor neuron denervation. Nusinersen and onasemnogene abeparvovec act via different molecular mechanisms and display different delivery effectiveness. Nusinersen loading has been associated with dramatic and persistent drop in neurofilament levels in 2 copy infants, and has a long half life that could persist through the gene therapy dosing and transduction process. Thus, in a presymptomatic clinical cohort of infants with 2 SMN2 copies, we hypothesize that sequential administration of nusinersen and onasemnogene abeparvovec could present a synergic effect in these vulnerable SMA infants, without the need to continue long term combinatorial therapy. In already symptomatic 2 copy infants, near simultaneous dosing at the earliest opportunity, as demonstrated in the cohort included here, could maximize survival of the greatest number of at risk motor neurons and help ensure maximal transduction efficacy. Here, we report for the first time a comprehensive safety dataset including the levels of circulating liver enzymes from SMA cases receiving treatment with only onasemnogene abeparvovec, and SMA cases receiving combinatorial therapy with nusinersen and onasemnogene abeparvovec in their first months of life.

### **Methods**

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

This is a longitudinal cohort study including a total of 14 SMA newborns or infants treated in the first months of life at the Massachusetts General Hospital (MGH), including 8 infants who received treatment with onasemnogene abeparvovec and 6 infants who received combinatorial treatment with nusinersen and then

5

onasemnogene abeparvovec. All patients received prednisolone 48 hours prior to onasemnogene abeparvovec dosing and continued for 2-3 months post dosing as per standard of care. None of these patients were receiving risdiplam (Evrysdi, Roche). Of note, all patients receiving only onasemnogene abeparvovec were treated early in life at the pre-symptomatic stage, while all patients receiving co-therapy with nusinersen and onasemnogene abeparvovec in this study demonstrated clinical symptoms at dosing. The primary outcomes of this study are circulating alanine aminotransferase (ALT) and aspartate transaminase (AST) levels measured as biomarkers of potential hepatoxicity. In addition to the absolute values, the fold change from the baseline (i.e. measurements taken before injection) ALT and AST levels were also calculated for each individual patient and presented. Circulating gamma-glutamyl transferase, troponin T-hs Gen 5 (Troponin T), white blood counts, platelets and albumin levels were also determined as secondary outcomes along with any clinical adverse effect manifestation. Reference normal ranges were determined based on MGH laboratory references. Reference values from the Mayo Clinic and the University of California San Francisco (UCSF) Children's are also provided. SMN1 and SMN2 copy numbers were determined using quantitative polymerase chain reaction as previously described<sup>12</sup>. All other outcomes were obtained from the clinical laboratory in association with research visits in the SPOT SMA Longitudinal Pediatric Data Repository (LPDR) housed within the Research Electronic Data Capture Web Application at the Newborn Screening Translational Research Network<sup>13</sup>. Written informed parental consent was obtained from all participants under Institutional Ethics Review Board at the MGH (protocol #2016-P000469). Distribution of age range and sex are presented in **Table 1**.

# Results

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

We determined circulating ALT and AST levels in two cohorts of SMA patients receiving gene therapy early in life (**Table 1**). The first cohort included 8 SMA infants ages 20 – 190 days old treated at the presymptomatic stage. They received only onasemnogene abeparvovec treatment (**Figures 1A-H**). The second cohort included 6 SMA infants and 1 child who received both nusinersen and onasemnogene abeparvovec (**Figures 2A-F**). Only 1 of 8 presymptomatic infants dosed with onasemnogene abeparvovec had elevated circulating ALT and AST levels, occurring within a few days post injection (**Figure 1B**),

6

showing a 20-fold change in ALT and 9-fold change in AST (Figure 3A-B, 3E-F). This specific case was a subject with 3 SMN2 copies. Importantly, increased ALT and AST levels returned to normal within 3 months after the injection (Figure 1B, 3A-B, 3E-F). For the second cohort including symptomatic patients with 2 SMN2 copies, we observed 3 out of 6 cases with elevated circulating ALT and AST levels post onasemnogene abeparvovec injection (Figure 2A-F). Two patients showed similar changes, both displaying about a 4.5-fold increase in ALT and a 4-to-7-fold increase in AST. Another patient showed a 28-fold change in ALT and 6-fold change in AST from baseline (Figure 3C-D, 3E-F). Of note, this patient was also the oldest dosed patient. Increased ALT and AST levels also returned to normal levels around 3 months after the injection and were maintained at normal ranges during follow-up (Figure 2A, 2C, 2E, 3C-D, 3E-F). Taken together, these data closely parallel previously published clinical trial data demonstrating that some infants with SMA experience transient hepatotoxicity after gene therapy even when prednisolone is co-administered, but these effects are transient and typically return to normal by three months. Importantly, all enrolled patients had normal albumin levels and no indications of malnutrition or chronic liver disease (Table 2 and Supplementary Table 1). As complementary analysis, we observed increased levels of troponin T and platelets in most of the SMA infants and children (Table 2 and Supplementary File 1), indicating potential myocardial injury and thrombocytosis. These increased levels are most likely part of the natural course of SMA pathophysiology since they were not observed as a direct consequence of any therapy. Other measurements such as circulating white blood counts and platelets also demonstrated some specific values out of normal range during this longitudinal follow-up study, but did not clearly correlate with treatment (Table 2 and Supplementary File 1). Moreover, we observed multiple mild or moderate clinical events during the follow up of this study, but only 4 patients treated with either gene therapy or co-therapy showed at least one severe adverse event related to a cardiac, respiratory, or nutritional issue (Table 3). These adverse events were managed in hospital visits. They were not clearly associated with treatment response, and were considered most likely related to the primary underlying diagnosis. Altogether, these findings validate previous evidence showing that patients with SMA need to be closely monitored after transformative gene therapy is administered in the real world clinical setting.

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

7

## Discussion

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

Taking advantage of our longitudinal database (MGH SPOT SMA LPDR) that includes SMA cases treated early in life with onasemnogene abeparvovec, we were able to evaluate several markers related to the safety of gene therapy. Our findings indicate that some SMA patients can present hepatotoxicity within a few days after receiving the gene therapy. More drastic changes in ALT and AST values were notably observed in patients dosed with gene therapy at an older age in the second cohort in contrast to the first cohort whose age at dosing was younger on average, reemphasizing the importance of initiating therapy in 2 SMN2 copy infants at the earliest opportunity. These effects are transient and return to normal levels within three months post injection. Corroborating these single center observations, a study combining data from 5 previous clinical trials has observed liver-related adverse events in 34% of SMA patients treated with gene therapy. Variable liver response to the gene therapy was also clearly observed in the original trial establishing the single-dose gene therapy for SMA and emphasized the importance of co-treatment with oral prednisolone to mitigate immune-mediated hepatotoxicity<sup>8</sup>. Prednisolone doses can be adjusted when necessary in each specific SMA case<sup>8</sup>. Here, we observed a total of 4 SMA cases suggesting at least transient liver injury in spite of prednisolone treatment, but without any evident long-lasting consequences. We report longitudinal safety data from 6 symptomatic SMA cases with only 2 SMN2 copies that have been treated with co-therapy with onasemnogene abeparvovec and nusinersen. These patients are achieving motor milestones that were not expected in the natural history of the disease and the present data also suggest that side effects of these therapies are transient and can be controlled by closely monitoring each patient. These results demonstrate the safety for sequential and coincident nusinersen therapy during the induction process for gene therapy. Nusinersen treatment administered pre-gene therapy treatment theoretically provides an advantage over risdiplam, given its prolonged treatment effect following an initial loading period. However, we did not examine the impact or safety of sequential or coincident treatment with risdiplam in this study, and thus our conclusions are limited. In line with our findings, another recent study including 2 SMA cases that received co-therapy with nusinersen and onasemnogene abeparvovec also reported no apparent increased burden of adverse effects<sup>11</sup>. This possibility of combining therapies for SMA patients has presented itself as particularly interesting for the SMA community. Based on our current data, we advocate for additional studies analyzing different outcomes in SMA patients receiving co-therapies and

an open discussion about the advantages and disadvantages of combining these treatments. We hypothesize that there is limited to no benefit in continuing a second therapy once gene therapy has been delivered in a truly presymptomatic infant with 2 copies. However, there may be in an infant with some evident denervation and an emerging clinical phenotype. In our experience, progressive denervation can sometimes occur quite precipitously in a 2 copy infant between ordering and dosing gene therapy. Thus, biomarkers such as CMAP, MUNE, or robust serum biomarkers must be integrated into the current clinical paradigm since clinical exam and even functional motor tests remain insufficient for this purpose.

We observed increased troponin T and variable platelet levels in SMA patients, which are markers of increased risk for myocardial injury and thrombocytosis. While damage in motor neurons accounts for the earliest manifestations in SMA infants, evidence indicates that other tissues contribute to the SMA pathophysiology due to the direct effects of SMN deficiency in tissues other than motoneurons, or indirect effects due to the severe denervation status<sup>14,15</sup>. In this context, a multidisciplinary approach is critical to monitor and provide the best care for SMA patients. Markers assessed in the current study corroborate the premise of systemic disease manifestation and highlight the importance of close monitoring for emergence of disease phenotypes beyond muscle denervation.

In summary, this case series analysis study highlights the importance of early intervention with gene therapy and other molecular treatments for SMA and the need for close monitoring of treatment responses beyond muscle denervation in the real world clinical setting.

# **Data Availability Statement**

All data relevant to this study are contained within the manuscript.

# **Acknowledgements**

We are grateful to all the patients and families who participated in this study.

#### **Author Contributions**

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

K.J.S. and C.R.R.A. directed the research project. R.G.S., S.D.L., E.A.A., E.R., and K.J.S. collected clinical data. R.G.S., L.L.H., S.D.L., E.A.A., E.R., K.J.S., and C.R.R.A. analyzed the data and participated in the data interpretation. L.L.H., K.J.S. and C.R.R.A. drafted the manuscript. All authors reviewed and approved the final manuscript. **Funding** C.R.R.A. received a fellowship from the MGH ECOR. K.J.S. was funded by NIH NICHD R01HD054599, NIH NINDS R21NS108015, Biogen, and Cure SMA. **Ethical Approval** Ethical approval and written informed parental consent were obtained from all participants under Institutional Ethics Review Boards at the Massachusetts General Hospital (protocol 2016P000469). **Competing Interests** C.R.R.A. and K.J.S. are inventors on a patent filed by Mass General Brigham that describes genome engineering technologies to treat SMA. K.J.S. was a recipient of a grant from Biogen and received clinical trial funding from AveXis and Biogen. C.R.R.A is a consultant for Biogen and holds stocks in publicly traded companies developing gene therapies. The other authors declare no competing interests.

# References

- 1. Groen, E. J. N., Talbot, K. & Gillingwater, T. H. Advances in therapy for spinal muscular atrophy:
- 214 promises and challenges. *Nat. Rev. Neurol.* **14**, 214–224 (2018).
- 2. Finkel, R. S. et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N.
- 216 Engl. J. Med. 377, 1723–1732 (2017).
- 3. Hagenacker, T. et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional,
- multicentre, observational cohort study. *Lancet Neurol.* **19**, 317–325 (2020).
- 4. Strauss, K. A. et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2
- at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. *Nat. Med.* **28**, 1381–1389
- 221 (2022).
- 5. Strauss, K. A. et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of
- SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat. Med. 28, 1390–1397
- 224 (2022).
- 6. Day, J. W. et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal
- muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm,
- 227 multicentre, phase 3 trial. *Lancet Neurol.* **20**, 284–293 (2021).
- 228 7. Chand, D. et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101)
- for the treatment of spinal muscular atrophy. *J. Hepatol.* **74**, 560–566 (2021).
- 8. Mendell, J. R. et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N. Engl. J.
- 231 *Med.* **377**, 1713–1722 (2017).
- 9. Al-Zaidy, S. A. & Mendell, J. R. From Clinical Trials to Clinical Practice: Practical Considerations for
- Gene Replacement Therapy in SMA Type 1. Pediatr. Neurol. 100, 3–11 (2019).
- 234 10. Mendell, J. R. et al. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene
- Abeparvovec in Spinal Muscular Atrophy. *JAMA Neurol.* **78**, 834 (2021).
- 236 11. Lee, B. H. et al. Combination therapy with nusinersen and AVXS-101 in SMA type 1. Neurology
- **93**, 640–641 (2019).
- 238 12. Prior, T. W. et al. A Positive Modifier of Spinal Muscular Atrophy in the SMN2 Gene. Am. J. Hum.
- 239 Genet. **85**, 408–413 (2009).

11

240 13. Alves, C. R. R. *et al.* Implications of circulating neurofilaments for spinal muscular atrophy

242 14. Lipnick, S. L. *et al.* Systemic nature of spinal muscular atrophy revealed by studying insurance

treatment early in life: A case series. Mol. Ther. Methods Clin. Dev. 23, 524-538 (2021).

- 243 claims. *PLOS ONE* **14**, e0213680 (2019).
- 244 15. Nery, F. C. et al. Impaired kidney structure and function in spinal muscular atrophy. Neurol.
- 245 Genet. **5**, e353 (2019).

241

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

**Table 1.** Information of patients with SMA receiving onasemnogene abeparvovec early in life.

Subject	Sex	Age range at dosing (days)				
Onasemnoge	ne abeparvovec monothe	rapy in presymptomatic newborns and infants up	to ~ 6 months of age (n = 8)			
1	F	31-35				
2	M	21-25				
3	F	16-20				
4	F	81-85				
5	F	36-40				
6	M	186-190				
7	F	101-105				
8	M	171-175				
Combinatori	ial therapy with onasemno	gene abeparvovec (AVXS) and nusinersen in a s	symptomatic cohort (n = 6)			
9	F	Nusinersen: 71-75 AVX	S: 936-940			
10	F	Nusinersen: 91-95 AVX	(S: 96-100			
11	F	Nusinersen: 46-50 AVX	S: 141-145			
12	М	Nusinersen: 76-80 AV	XS: 81-85			
13	М	Nusinersen: 16-20 AV	XS: 26-30			
14	M	Nusinersen: 6-10 AVX	(S: 96-100			

Table 2. Clinical characteristics of patients with SMA receiving onasemnogene abeparvovec early in life.

Out is at	SMN2	GGT	Troponin T	WBC	Platelets	Albumin	HGB	CK	CK-MB	No. of
Subject	(copies)	(U/L)	(ng/L)	(K/uL)	(K/uL)	(g/dL)	(g/dL)	(U/L)	(ng/mL)	Adverse Events
	Onase	emnogene	abeparvovec m	onotherapy in p	resymptomatic	newborns an	nd infants up	to ~ 6 months	of age (n = 8)	
1	2	14-66	Not tested	6.58-13.16	346-497	3.7-4.8	10.5-13.2	125-618	8.5-32.8	9 (1 SAE)
2	2	10	<50	10.8-11.2	371-378	3.9-4.4	14.1-14.7	Not tested	Not tested	1
3	3	12-76	5	10.40-13.50	365-730	3.8-4.7	9.7-13.7	40-154	3.8-7.1	4
4	3	11-29	7-29	7.06-11.6	319-446	3.7-4.4	9.8-12.1	49-168	3.2-5.9	0
5	3	7-13	<6-25	13.44-19.85	347-609	3.7-4.5	11.2-12	79-82	Not tested	10
6	4+	11-26	7-28	5.61-10.82	422-914	4.0-4.8	8.9-14.3	188	5.8	0
7	3	7-16	6-7	6.02-9.56	363-407	4.2-4.4	10.4-12	95-211	4.4-10.8	9
8	4+	18-34	8-21	3.96-7.48	181-333	4.3-4.6	11.5-12.7	229	10.8	1
	Combin	natorial the	rapy with onase	emnogene abepa	arvovec (AVXS	) and nusiner	rsen in a sym	ptomatic coho	rt (n = 6)	
9	2	7-72	19-61	7.23-13.11	156-541	3.5-4.7	9.5-14.8	54-74	5.2-7.9	8 (2 SAEs)
10	2	5-50	33-82	9.74-14.72	318-541	4.1-4.9	10.6-12.9	106-248	9.9	5 (1 SAE)
11	2	6-18	60	6.75-13.50	316-476	4.2-4.7	10.9-13.2	105-150	15.4	16
12	2	8-46	41-90	5.71-10.85	289-423	4.0-5.1	11-14	126-148	15.5-24.6	8
13	2	4-22	42-61	7.07-11.9	267-799	3.3-4.7	9.4-13.8	160-141	Not tested	9 (3 SAEs)
14	2	11-23	25-68	7.04-8.18	199-399	4.0-4.8	10.9-12	Not tested	Not tested	1

GGT: Gamma-glutamyl transferase; Troponin T: Troponin T-hs Gen 5; WBC; White blood cell count. SAE: severe adverse event

Table 3. Summary of adverse events (AEs) in patients with SMA receiving onasemnogene abeparvovec early in life.

	Mild/Moderate	Severe/Hospital Visit Needed	Total	<u>%</u>
Fever	8	1	9	11.4%
GI	9		9	11.4%
Cardiac/Acute life				
threatening	1	1	2	2.5%
Respiratory	6	3	9	11.4%
Orthopedic	5		5	6.3%
Nutritional	1	1	2	2.5%
Other	39	4	43	54.4%
TOTAL AEs	69	7	79	
%	87.3%	8.9%		





